EP Patent

EP2371357B1 — Oral formulations and lipophilic salts of methylnaltrexone

Assigned to Wyeth LLC · Expires 2017-02-01 · 9y expired

What this patent protects

Patent listed against methylnaltrexone-bromide.

Drugs covered by this patent

methylnaltrexone-bromide (METHYLNALTREXONE BROMIDE)

Patent Metadata

Patent number: EP2371357B1
Jurisdiction: EP
Classification: —
Expires: 2017-02-01
Drug substance claim: No
Drug product claim: No
Assignee: Wyeth LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.